<html>
<head>
<meta charset="UTF-8"/>
<meta name="tikaGenerated" content="true"/>
<meta name="date" content="2018-11-22T02:30:47Z"/>
<meta name="xmp:CreatorTool" content="Acrobat PDFMaker 17 for Word"/>
<meta name="Company" content="SA Health"/>
<meta name="Keywords" content="atenolol, neonatal medication guidelines, tachyarrhythmia, hypertension"/>
<meta name="subject" content="Neonatal Medication Guideline"/>
<meta name="dc:creator" content="SA Maternal and Neonatal Community of Practice"/>
<meta name="dcterms:created" content="2018-11-22T02:30:42Z"/>
<meta name="Last-Modified" content="2018-11-22T02:30:47Z"/>
<meta name="dcterms:modified" content="2018-11-22T02:30:47Z"/>
<meta name="title" content="Atenolol"/>
<meta name="Last-Save-Date" content="2018-11-22T02:30:47Z"/>
<meta name="meta:save-date" content="2018-11-22T02:30:47Z"/>
<meta name="dc:title" content="Atenolol"/>
<meta name="modified" content="2018-11-22T02:30:47Z"/>
<meta name="cp:subject" content="Neonatal Medication Guideline"/>
<meta name="Content-Type" content="application/pdf"/>
<meta name="creator" content="SA Maternal and Neonatal Community of Practice"/>
<meta name="meta:author" content="SA Maternal and Neonatal Community of Practice"/>
<meta name="dc:subject" content="atenolol, neonatal medication guidelines, tachyarrhythmia, hypertension"/>
<meta name="meta:creation-date" content="2018-11-22T02:30:42Z"/>
<meta name="created" content="Thu Nov 22 13:00:42 ACDT 2018"/>
<meta name="xmpTPg:NPages" content="2"/>
<meta name="Creation-Date" content="2018-11-22T02:30:42Z"/>
<meta name="SourceModified" content="D:20181119053512"/>
<meta name="meta:keyword" content="atenolol, neonatal medication guidelines, tachyarrhythmia, hypertension"/>
<meta name="Author" content="SA Maternal and Neonatal Community of Practice"/>
<meta name="producer" content="Adobe PDF Library 15.0"/>
</head>
<body>
<pre>
South Australian Neonatal Medication Guidelines 

Atenolol 
 5mg/mL oral mixture 

  Department for Health and Ageing, Government of South Australia. All rights reserved.  

INFORMAL COPY WHEN PRINTED  Page 1 of 2 

Public-I4-A1 
 
 

Note:
This guideline provides advice of a general nature.  This statewide guideline has been prepared to promote and facilitate 
standardisation and consistency of practice, using a multidisciplinary approach.  The guideline is based on a review of 
published evidence and expert opinion.  
Information in this statewide guideline is current at the time of publication.  
SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not 
sponsor, approve or endorse materials on such links. 
Health practitioners in the South Australian public health sector are expected to review specific details of each patient and 
professionally assess the applicability of the relevant guideline to that clinical situation. 
If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the 
patient s medical record, the decision made, by whom, and detailed reasons for the departure from the guideline. 
This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are 
responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful 
confidential discussion. This includes: 

  The use of interpreter services where necessary, 
  Advising consumers of their choice and ensuring informed consent is obtained, 
  Providing care within scope of practice, meeting all legislative requirements and maintaining standards of 

professional conduct, and  
  Documenting all care in accordance with mandatory and local requirements 

Dose and Indications 

Tachyarrhythmia (e.g. supra ventricular tachyarrhythmia), hypertension 

Oral 

0.5 to 2mg/kg per day in 1 to 2 divided doses  

Preparation and Administration 
The oral mixture contains 5mg/mL of atenolol. 

Dose 1mg 2mg 3mg 4mg 5mg 6mg 

Volume 0.2mL 0.4mL 0.6mL 0.8mL 1mL 1.2mL 

Adverse Effects 
Common 

Cold extremities, diarrhoea, bradycardia, hypotension, heart failure, alteration of glucose and 
lipid metabolism 

Infrequent 

Rash, nasal congestion, heart block 

Rare 

Hypersensitivity reactions, thrombocytopenia, liver function abnormalities 

 



South Australian Neonatal Medication Guidelines 

Atenolol  
 5mg/mL oral mixture 
 

 

 
INFORMAL COPY WHEN PRINTED  Page 2 of 2 

Public-I4-A1 
 
 

Monitoring  
&gt; Monitor heart rate, blood pressure and observe for bronchospasm hourly for 3 hours after 

the first dose. 
&gt; Monitor blood glucose levels 3 hours after the first dose.  
&gt; Consider the above monitoring with every mg/kg increase in dosage. 

Practice Points 
&gt; When stopping treatment, reduce dose gradually as abrupt withdrawal may exacerbate 

arrhythmias or precipitate rebound hypertension. 
&gt; If dose is greater than 1mg/kg, it can be split into two doses. 
&gt; As a selective  1 agonist, atenolol is less likely to cause hypoglycaemia compared to 

propranolol. 
&gt; May need a dose reduction in severe renal impairment.  
&gt; Atenolol is not available in a parenteral form.  If IV therapy required, consult paediatric 

cardiologist. 
  
 
Document Ownership &amp; History 

Developed by: SA Maternal, Neonatal &amp; Gynaecology Community of Practice 
Contact: Health.NeoMed@sa.gov.au 
Endorsed by:  SA Health Safety and Quality Strategic Governance Committee 
Next review due:   15 November 2023 
ISBN number:  978-1-76083-009-0 
PDS reference:  CG287 
Policy history: Is this a new policy (V1)?  N 
 Does this policy amend or update and existing policy?   Y 
 If so, which version? V1.1 
 Does this policy replace another policy with a different title?  N 
 If so, which policy (title)? 
 
 
 

Approval 
Date 

Version 
Who approved New/Revised 
Version 

Reason for Change 

15/11/18 V2 
SA Health Safety and Quality 
Strategic Governance Committee 

Formally reviewed in line with 5 year 
scheduled timeline for review. 

9/3/2018 V1.1 
SA Health Safety and Quality 
Strategic Governance Committee 

Review date extended to 5 years following 
risk assessment. New template 

13/8/2013 V1 
SA Health Safety and Quality 
Strategic Governance Committee 

Original SA Health Safety and Quality 
Strategic Governance Committee approved 
version 

 



</pre>
</body>
</html>